Summary of Study ST000898
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000624. The data can be accessed directly via it's Project DOI: 10.21228/M8109M This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST000898 |
Study Title | TAp73 is a marker of glutamine addiction in medulloblastoma |
Study Type | siRNA constructs targeting p73 (ID: 2671-AMBION) and a non-targeting control siRNA (scramble) were transfected with 10 pM siRNA with lipofectamine 3000 according to the supplier’s protocol for 48 hours |
Study Summary | Metabolically-targeted therapies hold the promise of offering an effective and less toxic treatment for tumours including medulloblastoma, the most common malignant brain tumour of childhood. Current treatment relies on the sensitivity of these tumours to DNA damage that was discovered more than 50 years ago. Finding new tumour-specific susceptibilities to complement sensitivity to DNA damage is key to developing new more effective adjuvant therapies. The specific metabolic program of tumours is an attractive vulnerability, as restriction diet are low cost and easy to implement. Here, we present compelling pre-clinical evidence that glutamine restriction diet can be used as an adjuvant treatment for p73-expressing medulloblastoma. |
Institute | Queen Mary University of London |
Department | Blizard Institute |
Laboratory | Centre for Genomics and Child Health |
Last Name | Marino |
First Name | Silvia |
Address | 4 Newark Street, E1 2AT, London |
s.marino@qmul.ac.uk | |
Phone | +44 20 7882 2360 |
Submit Date | 2017-08-24 |
Num Groups | 2 |
Total Subjects | 18 |
Study Comments | We include 3 biological replicate with 3 technical replicates for each condition. |
Raw Data Available | Yes |
Analysis Type Detail | LC-MS |
Release Date | 2017-11-20 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000624 |
Project DOI: | doi: 10.21228/M8109M |
Project Title: | TAp73 is a marker of glutamine addiction in medulloblastoma |
Project Type: | siRNA constructs targeting p73 (ID: 2671-AMBION) and a non-targeting control siRNA (scramble) were transfected with 10 pM siRNA with lipofectamine 3000 according to the supplier’s protocol for 48 hours |
Project Summary: | Metabolically-targeted therapies hold the promise of offering an effective and less toxic treatment for tumours including medulloblastoma, the most common malignant brain tumour of childhood. Current treatment relies on the sensitivity of these tumours to DNA damage that was discovered more than 50 years ago. Finding new tumour-specific susceptibilities to complement sensitivity to DNA damage is key to developing new more effective adjuvant therapies. The specific metabolic program of tumours is an attractive vulnerability, as restriction diet are low cost and easy to implement. Here, we present compelling pre-clinical evidence that glutamine restriction diet can be used as an adjuvant treatment for p73-expressing medulloblastoma. |
Institute: | Queen Mary University of London |
Department: | Blizard Institute |
Laboratory: | Centre for Genomics and Child Health |
Last Name: | Marino |
First Name: | Silvia |
Address: | 4 Newark Street, E1 2AT, London |
Email: | s.marino@qmul.ac.uk |
Phone: | +44 20 7882 2360 |
Funding Source: | Children with Cancer UK fellowship (Reference Nº2014/178) |